IL-8 as a urinary biomarker for the detection of bladder cancer

[1]  C. Greenhill.  Esophageal cancer: Matrix metalloproteinase 10 is associated with survival in patients with esophageal squamous cell carcinoma , 2012, Nature Reviews Gastroenterology &Hepatology.

[2]  K. Shedden,et al.  Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free Quantification , 2011, Clinical Cancer Research.

[3]  J. Overgaard,et al.  Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival , 2010, Acta oncologica.

[4]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[5]  K. Loughlin,et al.  A novel approach to using matrix metalloproteinases for bladder cancer. , 2009, The Journal of urology.

[6]  G. Bahar,et al.  Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors. , 2009, Clinical genitourinary cancer.

[7]  S. Goodison,et al.  Urine-based assays for the detection of bladder cancer. , 2009, Biomarkers in medicine.

[8]  Paul R Young,et al.  Bladder Cancer–Associated Gene Expression Signatures Identified by Profiling of Exfoliated Urothelia , 2009, Cancer Epidemiology Biomarkers & Prevention.

[9]  Holly Janes,et al.  Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.

[10]  H. Grossman,et al.  Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology , 2008 .

[11]  I. Leibovitch,et al.  Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow‐up of bladder cancer in patients with benign urine cytology , 2007, Cancer.

[12]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[13]  M. Swellam,et al.  Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. , 2007, European urology.

[14]  M. Nishikido,et al.  Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. , 2007, European urology.

[15]  Andrew J. Ewald,et al.  Matrix metalloproteinases and the regulation of tissue remodelling , 2007, Nature Reviews Molecular Cell Biology.

[16]  Trairak Pisitkun,et al.  Discovery of Urinary Biomarkers* , 2006, Molecular & Cellular Proteomics.

[17]  E. Messing,et al.  Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. , 2005, Urology.

[18]  E. Messing,et al.  Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. , 2005, Urology.

[19]  T. Ørntoft,et al.  Gene expression profiling of noninvasive primary urothelial tumours using microarrays , 2005, British Journal of Cancer.

[20]  B. Reiser,et al.  Estimation of the Youden Index and its Associated Cutoff Point , 2005, Biometrical journal. Biometrische Zeitschrift.

[21]  M. Bibby,et al.  Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. , 2005, Urology.

[22]  T. Koçak,et al.  Determination of diagnostic and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer. , 2004, Clinical biochemistry.

[23]  C. Dinney,et al.  Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  R. Weiss,et al.  Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. , 2003, Urology.

[25]  H. Schmoll,et al.  F.L. Greene, D.L. Page, I.D. Fleming et al. (eds). AJCC Cancer Staging Manual, 6th edition , 2003 .

[26]  P. Stieber,et al.  Measurements of Complement Factor H-Related Protein (BTA-TRAK™ Assay) and Nuclear Matrix Protein (NMP22 Assay) – Useful Diagnostic Tools in the Diagnosis of Urinary Bladder Cancer? , 2003, Clinical chemistry and laboratory medicine.

[27]  C. Gatsonis,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, BMJ : British Medical Journal.

[28]  Anant Kumar,et al.  Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. , 2002, The Journal of urology.

[29]  O. Oge,et al.  The BTA stat test is nonspecific for hematuria: an experimental hematuria model. , 2002, The Journal of urology.

[30]  A L Zhou,et al.  Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. , 2000, American journal of physiology. Heart and circulatory physiology.

[31]  F. Algaba,et al.  Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. , 2000, The Journal of urology.

[32]  J. Fata,et al.  Cellular turnover and extracellular matrix remodeling in female reproductive tissues: functions of metalloproteinases and their inhibitors , 2000, Cellular and Molecular Life Sciences CMLS.

[33]  A. Waage,et al.  Serum syndecan-1: a new independent prognostic marker in multiple myeloma. , 2000, Blood.

[34]  L. Kiemeney,et al.  Epidemiology of Bladder Cancer , 1999, European Urology.

[35]  R N Hoover,et al.  Occupational risks of bladder cancer in the United States: II Nonwhite men. , 1989, Journal of the National Cancer Institute.

[36]  G. Farrow,et al.  Urine cytology of transitional cell neoplasms. , 1979, The Urologic clinics of North America.

[37]  T. Habuchi.  Prognostic Markers for Bladder Cancer , 2011 .

[38]  M. J. Requena Tapia,et al.  [The 2004 WHO classification of bladder tumors: a summary and commentary]. , 2007, Actas urologicas espanolas.

[39]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[40]  R N Hoover,et al.  Occupational risks of bladder cancer in the United States: I. White men. , 1989, Journal of the National Cancer Institute.

[41]  S. Baron,et al.  Hemoglobinuria detection in 195 urology patients. , 1988, Cancer detection and prevention.